News Update August 2019 on Oncologics
News update on Oncologics for the month of August 2019
Published Date: August 2019
Location: Hyderabad, Telangana, India
Predictable adverse drug reactions (ADRs) which are unintended side effects are usually drug-induced injury in the body that are fatal in extremes. These adverse side effects occur after a single or prolonged exposure to one or multiple drugs. For eons, toxicology studies relied only on animal models to comprehend and characterize the toxicity of investigational drug candidates extrapolated to patient application.
On the other hand, animal models developed and known to the pharma researchers arealternatives to human models for human toxicity. The compelling evidence with Fialuridine drug which was developed as cure that killed patients due to hepatotoxicity, highlighted the need for more relevant predictive and real time models to predict human toxicity in pre-clinical stages.
Human sourced stem cells basedinvitro models are potential and compulsive models for toxicity testing during early stages of drug development. Stem cells with their self-renewing property and capabilities to differentiate into lineage specific tissue relevant matured cell types offer to model human liver, pancreas and heart in the labs. All other models (insilico, invitro), sources (biopsies, cadaveric), transformed cell lines being practised even at exploratory pre-clinical stages are insufficient as invitro systems in evaluating hepato, cardio and gastrointestinal toxicity of druggable candidates seeking convincing pre-clinical invitro systems closer to reality with predictive powers. The robustness of most of the invitro model systems would depend on the bio component’s availability, compatibility and the distinct features dictating the predictive signatures while the choice of the bio component (like human sourced stem cells versus all or any other) would make the model system predict the prognosis of the drug in clinics.
About www.transtoxbio.com products:
All human biological discards sourced primary progenitor adult stem cells based platforms that can predict toxicity related end points. Trans-MSC and Trans-HSC are the product platforms that have documented applications/use cases in establishing invitro systems to evaluate potential human organ toxicity related end points.
Transcell Oncologics’ cell based products portfolio (www.transtoxbio.com) is in talks with several Contract Research Organizations with established invitro toxicity testing capabilities to partner and supply/support with relevant products from it’s portfolio addressingtheir exploratory toxicity testings offerings.